Barclays PLC Biomarin Pharmaceutical Inc Transaction History

Barclays PLC

$288 Billion
Q1 2024

A detailed history of Barclays PLC transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Barclays PLC holds 5,254,520 shares of BMRN stock, worth $433 Million. This represents 0.16% of its overall portfolio holdings.

Number of Shares

5,254,520

Previous 5,288,893 0.65%

Holding current value

$433 Million

Previous $510 Million 10.01%

% of portfolio

0.16%

Previous 0.19%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$83.81 - $99.0 $2.88 Million - $3.4 Million	-34,373 Reduced 0.65%	5,254,520 $459 Million
Q4 2023 Feb 15, 2024	SELL	$76.22 - $98.51 $21.7 Million - $28 Million	-284,264 Reduced 5.1%	5,288,893 $510 Million
Q3 2023 Nov 07, 2023	BUY	$85.07 - $94.48 $248 Million - $275 Million	2,911,886 Added 109.42%	5,573,157 $493 Million
Q2 2023 Aug 03, 2023	BUY	$86.68 - $100.3 $91.6 Million - $106 Million	1,056,445 Added 65.83%	2,661,271 $231 Million
Q1 2023 May 04, 2023	SELL	$87.74 - $117.27 $33.1 Million - $44.3 Million	-377,663 Reduced 19.05%	1,604,826 $156 Million

Q4 2022 Feb 13, 2023	SELL	$80.93 - $108.63 $21.9 Million - $29.4 Million	-270,314 Reduced 12.0%	1,982,489 $205 Million
Q3 2022 Nov 03, 2022	BUY	$82.16 - $96.94 $7.16 Million - $8.45 Million	87,163 Added 4.02%	2,252,803 $191 Million
Q2 2022 Aug 12, 2022	BUY	$71.48 - $86.85 $143 Million - $174 Million	2,001,395 Added 1218.54%	2,165,640 $179 Million
Q1 2022 May 16, 2022	SELL	$74.28 - $92.69 $2.53 Million - $3.16 Million	-34,114 Reduced 17.2%	164,245 $12.7 Million
Q4 2021 Feb 14, 2022	SELL	$71.72 - $91.47 $772,496 - $985,223	-10,771 Reduced 5.15%	198,359 $17.5 Million
Q3 2021 Nov 09, 2021	BUY	$74.77 - $85.47 $1.13 Million - $1.29 Million	15,055 Added 7.76%	209,130 $16.2 Million
Q2 2021 Aug 13, 2021	BUY	$75.51 - $84.79 $696,126 - $781,679	9,219 Added 4.99%	194,075 $16.2 Million
Q1 2021 May 13, 2021	SELL	$74.73 - $90.69 $7.08 Million - $8.6 Million	-94,798 Reduced 33.9%	184,856 $14 Million
Q4 2020 Feb 11, 2021	BUY	$72.61 - $90.2 $4.13 Million - $5.13 Million	56,826 Added 25.5%	279,654 $24.5 Million
Q3 2020 Nov 12, 2020	SELL	$71.87 - $131.03 $4.52 Million - $8.25 Million	-62,955 Reduced 22.03%	222,828 $17 Million
Q2 2020 Aug 12, 2020	SELL	$79.55 - $124.22 $1.06 Million - $1.65 Million	-13,284 Reduced 4.44%	285,783 $35.3 Million
Q1 2020 May 13, 2020	SELL	$71.37 - $96.85 $7.39 Million - $10 Million	-103,556 Reduced 25.72%	299,067 $25.3 Million
Q4 2019 Feb 10, 2020	BUY	$64.27 - $86.37 $11 Million - $14.7 Million	170,459 Added 73.42%	402,623 $34 Million
Q3 2019 Nov 14, 2019	SELL	$67.4 - $85.11 $12.5 Million - $15.8 Million	-185,826 Reduced 44.46%	232,164 $15.6 Million
Q2 2019 Aug 14, 2019	BUY	$80.35 - $93.9 $10.4 Million - $12.2 Million	129,797 Added 45.04%	417,990 $35.8 Million
Q1 2019 May 15, 2019	BUY	$84.2 - $98.62 $2.75 Million - $3.23 Million	32,717 Added 12.81%	288,193 $25.6 Million
Q4 2018 Feb 14, 2019	SELL	$80.14 - $106.07 $10.8 Million - $14.3 Million	-134,679 Reduced 34.52%	255,476 $21.8 Million
Q3 2018 Nov 14, 2018	SELL	$93.92 - $105.72 $9.87 Million - $11.1 Million	-105,106 Reduced 21.22%	390,155 $37.8 Million
Q2 2018 Aug 14, 2018	BUY	$76.01 - $99.03 $10.1 Million - $13.1 Million	132,231 Added 36.42%	495,261 $46.7 Million
Q1 2018 May 15, 2018	BUY	$77.67 - $92.63 $578,253 - $689,630	7,445 Added 2.09%	363,030 $29.4 Million
Q4 2017 Feb 14, 2018	BUY	$80.76 - $95.13 $2.26 Million - $2.66 Million	27,936 Added 8.53%	355,585 $31.7 Million
Q3 2017 Nov 14, 2017	BUY	$80.6 - $94.95 $26.4 Million - $31.1 Million	327,649	327,649 $30.5 Million

Others Institutions Holding BMRN

# of Institutions

623

Shares Held

181M

Call Options Held

1.73M

Put Options Held

1.73M

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $15.3B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account